136 results
8-K
EX-10.2
a31ihhwc5
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
inlughec7999h5
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-99.1
z73y06htjzrk 2g
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
uct5xerr7ale9 t87dnl
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
tvwdry44
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
92p2m 61rryb
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
h32ml6jfmo
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
rui 3eubx00u
30 May 23
Business combination disclosure
4:21pm
8-K
hnx61 r6bqver5j7xs3
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
6b3i5ec74kz19qkd1z
22 May 23
Business combination disclosure
7:01am
8-K
rba1bu5njyt2ay446b
22 May 23
Other Events
6:59am
8-K
EX-99.1
eyuoeju5 79wavut
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
mk66cj0
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
thh qa6urxs
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm